<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285827</url>
  </required_header>
  <id_info>
    <org_study_id>CSL889_1001</org_study_id>
    <secondary_id>2019-001870-27</secondary_id>
    <nct_id>NCT04285827</nct_id>
  </id_info>
  <brief_title>Safety of Single Ascending Doses of CSL889 in Adult Patients With Stable Sickle Cell Disease</brief_title>
  <official_title>A Phase 1, Multi-Center, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Stable Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, first-in-human, multi-center, open-label, single ascending dose (SAD)&#xD;
      cohort study to evaluate the safety and tolerability, pharmacokinetics (PK), exploratory&#xD;
      pharmacodynamics (PD), and biomarkers of target engagement of CSL889 following single&#xD;
      intravenous (IV) doses in subjects with stable sickle cell disease (SCD). The study involves&#xD;
      sequential dose escalation of cohorts with between-group assessments of key safety and PK&#xD;
      variables.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with treatment-emergent adverse events (TEAEs) by Cohort</measure>
    <time_frame>Up to 32 days after start of CSL889 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with TEAEs by severity by Cohort</measure>
    <time_frame>Up to 32 days after start of CSL889 infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with TEAEs by causality by Cohort</measure>
    <time_frame>Up to 32 days after start of CSL889 infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of CSL889 by Cohort</measure>
    <time_frame>Up to 32 days after CSL889 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under CSL889 serum concentration-time curve (AUC) from time 0 to time t (AUC0-t) by Cohort</measure>
    <time_frame>Up to 32 days after CSL889 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of CSL889 by Cohort AUC extrapolated to infinity (AUC0-inf) by CSL889 dose level</measure>
    <time_frame>Up to 32 days after CSL889 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Cmax (tmax) of CSL889 by Cohort</measure>
    <time_frame>Up to 32 days after CSL889 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of CSL889 by Cohort</measure>
    <time_frame>Up to 32 days after CSL889 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of CSL889 by Cohort</measure>
    <time_frame>Up to 32 days after CSL889 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz) of CSL889 by Cohort</measure>
    <time_frame>Up to 32 days after CSL889 infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with detectable antibodies to CSL889 by Cohort</measure>
    <time_frame>Up to 32 days after CSL889 infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>CSL889 Cohort 1 (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSL889 administered as a single IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL889 Cohort 2 (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSL889 administered as a single IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL889 Cohort 3 (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSL889 administered as a single IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL889 Cohort 4 (Dose 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSL889 administered as a single IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL889 Cohort 5 (Dose 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSL889 administered as a single IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSL889 Cohort 6 (Dose 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSL889 administered as a single IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CSL889</intervention_name>
    <description>Administered as an IV infusion</description>
    <arm_group_label>CSL889 Cohort 1 (Dose 1)</arm_group_label>
    <arm_group_label>CSL889 Cohort 2 (Dose 2)</arm_group_label>
    <arm_group_label>CSL889 Cohort 3 (Dose 3)</arm_group_label>
    <arm_group_label>CSL889 Cohort 4 (Dose 4)</arm_group_label>
    <arm_group_label>CSL889 Cohort 5 (Dose 5)</arm_group_label>
    <arm_group_label>CSL889 Cohort 6 (Dose 6)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of SCD characterized by HbSS or SCD characterized by the compound&#xD;
             heterozygous state of the βS mutation with β0 thalassemia mutations (HbSβ0)&#xD;
&#xD;
          -  Aged 18 to 60 years, inclusive&#xD;
&#xD;
          -  Stable SCD for at least 30 days before Day 1&#xD;
&#xD;
          -  Subject is either not taking hydroxyurea and / or L-glutamine, or subject has been&#xD;
             taking hydroxyurea and / or L-glutamine for at least 30 days before Day 1 on a stable,&#xD;
             well tolerated regimen that is planned to continue without change throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hospitalization for vaso-occlusive crisis (VOC) or treated with parenteral pain&#xD;
             medications in other medical settings such as the emergency department or day hospital&#xD;
             for VOC during the past 30 days before Day 1&#xD;
&#xD;
          -  Blood transfusion within the 90 days before Day 1, or expecting blood transfusion&#xD;
             during the study&#xD;
&#xD;
          -  Weight &gt;110 kg (242 lbs)&#xD;
&#xD;
          -  Surgery within 30 days before Day 1 or any preplanned surgeries during the study&#xD;
             (minor surgeries may be permitted under local anesthesia before screening, with&#xD;
             permission of the medical monitor)&#xD;
&#xD;
          -  Female subjects who are pregnant or breastfeeding&#xD;
&#xD;
          -  Female subject of childbearing potential or fertile male subject either not using or&#xD;
             not willing to use an acceptable method of contraception to avoid pregnancy during the&#xD;
             study and for 30 days after receipt of CSL889.&#xD;
&#xD;
          -  Treatment with any other drug / biologic that is newly approved for SCD during the&#xD;
             conduct of this study within 90 days before Day 1.&#xD;
&#xD;
          -  Treatment with another investigational product within 30 days or within 5 half-lives&#xD;
             of the product (whichever is greater) before Day 1&#xD;
&#xD;
          -  Vaccination within 30 days before Day 1, or planned vaccination during the study&#xD;
&#xD;
          -  Body-mass index &lt; 16 kg/m2 or weight &lt; 50 kg (110 lbs)&#xD;
&#xD;
          -  History of anaphylactic-type reactions, transfusion related reaction, asthma, or&#xD;
             autoimmune disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Registration Coordinator</last_name>
    <phone>610-878-4000</phone>
    <email>clinicaltrials@cslbehring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Illinois Hospital and Health Science Systems</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guys and St. Thomas</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Early Phase Unit</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.&#xD;
Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.&#xD;
If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.</ipd_time_frame>
    <ipd_access_criteria>Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.&#xD;
An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.&#xD;
The requesting party must execute an appropriate data sharing agreement before IPD will be made available.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

